Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study.
暂无分享,去创建一个
L. Skov | J. Thyssen | M. Rasmussen | J. Maul | A. Egeberg | Jashin J. Wu | S. Thomsen | L. E. Bryld | David Thein | K. K. Ajgeiy | N. A. Rosenø
[1] L. Skov,et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis - a nationwide cohort study. , 2023, Journal of the American Academy of Dermatology.
[2] C. Griffiths,et al. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. , 2022, JAMA dermatology.
[3] Y. Lytvyn,et al. Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study , 2021, JAAD international.
[4] L. Teixeira,et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study , 2021, American Journal of Clinical Dermatology.
[5] B. Strober,et al. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry , 2021, Dermatologic therapy.
[6] R. Gniadecki,et al. Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis , 2020, Frontiers in Medicine.
[7] C. Griffiths,et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) , 2020, The British journal of dermatology.
[8] C. Peralta,et al. Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] L. Skov,et al. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. , 2019, Journal of the American Academy of Dermatology.
[10] M. Zorko,et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis , 2019, International journal of dermatology.
[11] M. Megna,et al. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. , 2019, Journal of the American Academy of Dermatology.
[12] C. Chi,et al. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence , 2018, Scientific Reports.
[13] L. Skov,et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis , 2018, The British journal of dermatology.
[14] N. Reynolds,et al. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) , 2017, The Journal of investigative dermatology.
[15] M. Sundaram,et al. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study , 2017, The Journal of dermatological treatment.
[16] A. Kimball,et al. Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.
[17] A. Burden,et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2015, The Journal of investigative dermatology.
[18] Yang Zhao,et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. , 2015, Journal of managed care & specialty pharmacy.
[19] L. Skov,et al. Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.
[20] P. C. van de Kerkhof,et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice , 2013, The Journal of dermatological treatment.
[21] A. Armstrong,et al. Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy , 2012, PloS one.